Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

For athletes and committed fitness enthusiasts, the mission to feel strong, steady, and maybe just a little bit invincible never really wraps up. Every few months, a new supplement struts onto the scene promising superhero stamina or laser-beam focus. Some people pledge their loyalty to coffee. Others swear by creatine. And plenty stick to their […]

The post The Science Behind Blackcurrants’ Effects on Fatigue and Muscle Performance appeared first on Medical News Bulletin.

Osteochondral allograft transplantation may be an effective treatment for pediatric patients with elbow osteochondritis dissecans, according to data recently published in The American Journal of Sports Medicine.
“The results of this study support this treatment as standard-of-care for children with elbow [osteochondritis dissecans (OCD)],” Crystal A. Perkins, MD, pediatric orthopedic surgeon at Children’s Healthcare of Atlanta, told Healio. “This evidence allows surgeons to have an informed discussion with patients and families with regards to anticipated surgical outcomes and ability to

ORLANDO — In this video, Brian T. Hill, MD, PhD, discusses a study presented at ASH Annual Meeting and Exposition which assessed a triplet nonchemotherapy regimen in older and medically unfit patients with diffuse large B-cell lymphoma.
In the study, patients with DLBCL who were considered unfit to receive R-CHOP chemotherapy received rituximab (Rituxan; Genentech, Biogen), polatuzumab vedotin (Polivy, Genentech) and glofitamab (Columvi, Genentech).
According to Hill, the triple regimen had good tolerability, a “very high and overall complete response rate” and durable

ORLANDO — An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual Meeting and Exposition.
The first four patients treated with KLN-1010 (Kelonia Therapeutics) achieved early minimal residual disease-negative response by 1 month and responses deepened over time, data from the phase 1 inMMyCAR study showed.
The two patients with the longest follow-up sustained MRD-negative bone marrow responses through 3 months. Memory phenotype T cells persisted in the

PARIS — A 5-year interim analysis of the PERCEIVE real-world study showed sustained improvement of light sensitivity in patients treated with voretigene neparvovec.
“This is the biggest real-world analysis of voretigene neparvovec,” Dominik Fischer, MD, said at the Euretina congress. “It’s the post-approval registry that captures all patients outside the U.S.”
The primary objective of PERCEIVE was to characterize the long-term safety profile of Luxturna (voretigene neparvovec-rzyl, Spark Therapeutics) via systematic collection of adverse events of special interest and serious adverse events in

Essilor Stellest 2.0 lenses with HALT Max technology led to significantly slower axial elongation than standard Essilor Stellest lenses, according to a study published in Translational Vision Science & Technology.
Essilor Stellest lenses slow myopia progression using highly aspherical lenslet target (HALT) technology, in which each lens has 11 concentric rings of contiguous aspherical lenslets that “create a volume of myopic defocus in front of the retina, following the shape of a child’s theoretical myopia retina,” study coauthor Björn Drobe, PhD, director of applied

SAN ANTONIO — In this video, Erica L. Mayer, MD, MPH, discusses data from the phase 3 lidERA trial demonstrating that giredestrant improved disease-free survival in early-stage, hormone receptor-positive, HER2-negative breast cancer.
Results of the trial — which compared giredestrant (Genetech, Roche), an oral selective estrogen receptor degrader, with standard-of-care endocrine therapy — were presented at San Antonio Breast Cancer Symposium.
Healio previously covered the lidERA trial here.
“Overall, these are really exciting data because this is the first time in 25

Mortality rates for Lennox Gastaut syndrome and Dravet syndrome, both developmental epileptic encephalopathies, were significantly higher than other forms of epilepsy, according to a poster at the American Epilepsy Society annual meeting.
“Developmental epileptic encephalopathies (DEEs) are among the most severe epilepsies, characterized by drug resistant seizures and significant developmental differences, yet we do not have adequate data about the burden of mortality in this population,” Elizabeth Donner, MD, MSc, FRCPC, head of the division of neurology at the Hospital for Sick Children in

The FDA has approved lerodalcibep-liga, a third-generation injectable PCSK9 inhibitor, to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, LIB Therapeutics announced.
Lerodalcibep-liga (Lerochol) is a once-monthly self-administered single small-volume subcutaneous injection with room temperature stability for up to 3 months, which enables patients to be flexible about where and when they administer the medication, according to a company press release.
As Healio previously reported, in the LIBerate-HR trial, presented in 2024 at

Findings from a phase 3 study provided additional evidence that the first pneumococcal vaccine made specifically for adults is well tolerated and provides strong protection for patients at an increased risk for pneumococcal disease.
The 21-valent pneumococcal vaccine, referred to as V116 (Capvaxive, Merck), was approved by the FDA and recommended by the CDC in June 2024 for the prevention of invasive disease and pneumonia among adults aged 18 years or older.
CDC vaccine advisors discussed several options and settled on recommending a shot of V116 as an option for adults aged 65 years or older